Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
33.7%
operating margin TTM
30.8%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | 27.09 |
| peg ratio | 0.02 |
| price to book ratio | 5.57 |
| price to sales ratio | 9.69 |
| enterprise value multiple | 27.02 |
| price fair value | 5.57 |
profitability ratios | |
|---|---|
| gross profit margin | 98.63% |
| operating profit margin | 30.8% |
| pretax profit margin | 34.94% |
| net profit margin | 33.7% |
| return on assets | 15.79% |
| return on equity | 22.86% |
| return on capital employed | 15.95% |
liquidity ratios | |
|---|---|
| current ratio | 5.62 |
| quick ratio | 5.32 |
| cash ratio | 2.29 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 1,620.68 |
| operating cycle | 1,681.05 |
| days of payables outstanding | 1,159.80 |
| cash conversion cycle | 521.25 |
| receivables turnover | 6.05 |
| payables turnover | 0.31 |
| inventory turnover | 0.23 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.01 |
| interest coverage | 16.23 |
| cash flow to debt ratio | 23.99 |
cash flow ratios | |
|---|---|
| free cash flow per share | 2.03 |
| cash per share | 4.91 |
| operating cash flow per share | 2.03 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | 23.99 |
| short term coverage ratios | 90.89 |
| capital expenditure coverage ratio | 978.78 |
Frequently Asked Questions
When was the last time Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported earnings?
Soleno Therapeutics, Inc. (SLNO) published its most recent earnings results on 07-05-2026.
What is Soleno Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Soleno Therapeutics, Inc. (NASDAQ:SLNO)'s trailing twelve months ROE is 22.86%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Soleno Therapeutics, Inc. (SLNO) currently has a ROA of 15.79%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did SLNO's net profit margin stand at?
SLNO reported a profit margin of 33.7% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is SLNO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.62 in the most recent quarter. The quick ratio stood at 5.32, with a Debt/Eq ratio of 0.01.